This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The paper did not report the criteria applied to the studies used to identify model parameters.
The age distribution and the age-specific prevalence of C. trachomatis infection were not derived from a review of the literature. Instead, they were derived using data from 5,078 annual visits by women universally screened in a publicly funded family planning clinic system in Philadelphia (Dicker et al., see Other Publications of Related Interest).
Sources searched to identify primary studies
The sources used to identify the primary studies were not listed.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Five studies provided the clinical and epidemiological parameters used in the model.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The number of clinic visits per year was 1,378 for women younger than 20 years, 1,548 for women aged 20 to 24 years, and 2,152 for women older than 24 years.
The prevalence of C. trachomatis was 0.106 amongst women younger than 20 years, 0.069 amongst women aged 20 to 24 years, and 0.023 amongst women older than 24 years.
The sensitivity of the DNA probe was 0.628 and the specificity was 0.998.
The sensitivity of the LCR test was 0.927 and the specificity was 0.999.
The effectiveness of doxycycline was 0.900.
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The effectiveness of azithromycin was 0.965.
Methods used to derive estimates of effectiveness
The authors made assumptions about the total budget for the screening and treatment of C. trachomatis per visit to the family planning clinic and the prevalence of C. trachomatis infection.
Estimates of effectiveness and key assumptions
The authors assumed that there was a budget of $6 per woman per visit. The authors used the positive rate with LCR in the Philadelphia-funded family programme (6%) as the prevalence of C. trachomatis infection.
Measure of benefits used in the economic analysis
The measures of benefits used were the number of women cured of C. trachomatis and the monetary benefit of the screening and treatment options.
Direct costs
This study considered the costs of the family planning clinic. These comprised the costs of performing the screening test, treatment and complications arising from uncured C. trachomatis. Resource use was estimated using the study model. The cost data were taken from published sources. The unit costs of the tests and treatments were reported. Discounting was not undertaken, but this was appropriate as the timeframe was one year. The cost data were taken from papers published between 1993 and 2000, but the costs do not appear to have been reflated to a single year. Estimates of resource use were derived from data published between 1991 and 2000. The price year was unclear.
Statistical analysis of costs
The cost data were treated deterministically.
Indirect Costs
No indirect costs were included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
A multi-level sensitivity analysis was undertaken to assess the robustness of the study findings and the generalisability of its results. The ranges of sensitivity, specificity and effectiveness data were reported. However, a justification for the ranges used was not provided. To assess the generalisability of the results, data from Oregon and Washington on the age distribution of women attending a family planning clinic and the prevalence of C. trachomatis were substituted into the model.
Estimated benefits used in the economic analysis
The number of women cured varied between 83 and 270 according to the screening coverage, the test selected and the treatment. For example:
if all women attending the family planning clinic were screened using the DNA test, and women with a positive test were treated with azithromycin, 183 women would be cured;
if women younger than 20 years were screened using the DNA test, and women with a positive test were treated with
